Medy-Tox Inc. (086900.KQ)
KRW 124900.0
(-2.42%)
KRW 124900.0
(-2.42%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 82.83 Billion KRW | -31.47% |
| 2022 | 120.86 Billion KRW | -9.07% |
| 2021 | 132.91 Billion KRW | -9.83% |
| 2020 | 147.41 Billion KRW | 43.9% |
| 2019 | 102.43 Billion KRW | 22.22% |
| 2018 | 83.81 Billion KRW | -26.63% |
| 2017 | 114.23 Billion KRW | 12.53% |
| 2016 | 101.5 Billion KRW | 304.56% |
| 2015 | 25.09 Billion KRW | 197.19% |
| 2014 | 8.44 Billion KRW | -0.52% |
| 2013 | 8.48 Billion KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 82.7 Billion KRW | -0.15% |
| 2024 Q2 | 92.89 Billion KRW | 12.32% |
| 2023 Q4 | 82.83 Billion KRW | -2.13% |
| 2023 FY | 82.83 Billion KRW | -31.47% |
| 2023 Q1 | 100.04 Billion KRW | -17.23% |
| 2023 Q2 | 84.68 Billion KRW | -15.35% |
| 2023 Q3 | 84.63 Billion KRW | -0.06% |
| 2022 FY | 120.86 Billion KRW | -9.07% |
| 2022 Q2 | 123.45 Billion KRW | 1.45% |
| 2022 Q1 | 121.68 Billion KRW | -8.45% |
| 2022 Q4 | 120.86 Billion KRW | -4.34% |
| 2022 Q3 | 126.35 Billion KRW | 2.35% |
| 2021 Q3 | 130.35 Billion KRW | -4.45% |
| 2021 Q4 | 132.91 Billion KRW | 1.96% |
| 2021 Q2 | 136.43 Billion KRW | -8.18% |
| 2021 Q1 | 148.58 Billion KRW | 1.18% |
| 2021 FY | 132.91 Billion KRW | -9.83% |
| 2020 Q4 | 146.85 Billion KRW | 11.24% |
| 2020 FY | 147.41 Billion KRW | 43.9% |
| 2020 Q3 | 132 Billion KRW | -12.49% |
| 2020 Q2 | 150.85 Billion KRW | 12.54% |
| 2020 Q1 | 134.04 Billion KRW | 31.36% |
| 2019 Q1 | 75.09 Billion KRW | -10.4% |
| 2019 Q2 | 87.23 Billion KRW | 16.17% |
| 2019 Q3 | 93.94 Billion KRW | 7.7% |
| 2019 Q4 | 102.04 Billion KRW | 8.62% |
| 2019 FY | 102.43 Billion KRW | 22.22% |
| 2018 FY | 83.81 Billion KRW | -26.63% |
| 2018 Q4 | 83.81 Billion KRW | -5.44% |
| 2018 Q3 | 88.63 Billion KRW | 7.32% |
| 2018 Q2 | 82.59 Billion KRW | 0.75% |
| 2018 Q1 | 81.97 Billion KRW | -28.24% |
| 2017 Q2 | 111.97 Billion KRW | 14.34% |
| 2017 Q1 | 97.92 Billion KRW | -3.53% |
| 2017 FY | 114.23 Billion KRW | 12.53% |
| 2017 Q4 | 114.23 Billion KRW | -2.04% |
| 2017 Q3 | 116.6 Billion KRW | 4.14% |
| 2016 Q3 | 97.27 Billion KRW | 289.32% |
| 2016 Q1 | 24.79 Billion KRW | -1.16% |
| 2016 FY | 101.5 Billion KRW | 304.56% |
| 2016 Q2 | 24.98 Billion KRW | 0.75% |
| 2016 Q4 | 101.5 Billion KRW | 4.35% |
| 2015 FY | 25.09 Billion KRW | 197.19% |
| 2015 Q4 | 25.09 Billion KRW | 180.8% |
| 2015 Q3 | 8.93 Billion KRW | 6.38% |
| 2015 Q2 | 8.39 Billion KRW | 2.89% |
| 2015 Q1 | 8.16 Billion KRW | -3.31% |
| 2014 Q1 | 8.58 Billion KRW | 1.14% |
| 2014 Q3 | 8.19 Billion KRW | 0.85% |
| 2014 Q4 | 8.44 Billion KRW | 3.05% |
| 2014 FY | 8.44 Billion KRW | -0.52% |
| 2014 Q2 | 8.12 Billion KRW | -5.36% |
| 2013 Q3 | 8.57 Billion KRW | 17.31% |
| 2013 Q1 | 8.07 Billion KRW | 0.0% |
| 2013 FY | 8.48 Billion KRW | 0.0% |
| 2013 Q2 | 7.31 Billion KRW | -9.42% |
| 2013 Q4 | 8.48 Billion KRW | -1.06% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Co., Ltd. | 62.7 Billion KRW | -32.094% |
| iNtRON Biotechnology, Inc. | 402.9 Million KRW | -20457.997% |
| BINEX Co., Ltd. | 53.5 Billion KRW | -54.802% |
| Bioneer Corporation | 44.63 Billion KRW | -85.552% |
| Anterogen.Co.,Ltd. | 9.74 Billion KRW | -750.377% |
| MEDIPOST Co., Ltd. | 52.33 Billion KRW | -58.261% |
| CrystalGenomics, Inc. | 32 Billion USD | -158.819% |
| Helixmith Co., Ltd | 20.22 Billion KRW | -309.488% |
| Chabiotech Co.,Ltd. | 449.63 Billion KRW | 81.578% |
| Peptron, Inc. | 9.13 Billion KRW | -806.934% |
| Amicogen, Inc. | 149.59 Billion KRW | 44.63% |
| Genexine, Inc. | 67.42 Billion KRW | -22.844% |
| HLB Therapeutics Co.,Ltd. | 10.02 Billion KRW | -726.454% |
| LegoChem Biosciences, Inc. | 12.64 Billion KRW | -555.098% |
| ALTEOGEN Inc. | 83.76 Billion KRW | 1.121% |
| PharmaResearch Co., Ltd. | 34.3 Billion KRW | -141.44% |
| SillaJen, Inc. | 9.69 Billion KRW | -754.217% |
| JETEMA, Co., Ltd. | 130.49 Billion KRW | 36.527% |
| OliX Pharmaceuticals,Inc | 39.35 Billion KRW | -110.457% |
| Genomictree Inc. | 1.83 Billion KRW | -4414.746% |
| MedPacto, Inc. | 8.6 Billion KRW | -862.68% |
| D&D Pharmatech | 8.13 Billion KRW | -918.282% |
| EASY BIO,Inc. | 82.27 Billion KRW | -0.671% |
| GI Innovation, Inc. | 3.72 Billion KRW | -2126.118% |